**INFORMED CONSENT FOR MEDICATION**
Dosage and / or Side Effect information last revised on 12/22/2016

Completion of this form is voluntary. If not completed, the medication cannot be administered without a court order unless in an emergency. This consent is maintained in the client’s record and is accessible to authorized users.

### MEDICATION CATEGORY

<table>
<thead>
<tr>
<th>Antipsychotic</th>
<th>Antidepressant</th>
<th>Bipolar/Mood Stabilizing Agent</th>
</tr>
</thead>
</table>

The anticipated dosage range is to be individualized, may be above or below the recommended range but no medication will be administered without your informed and written consent. Recommended daily total dosage range of manufacturer, as stated in *Physician’s Desk Reference* (PDR) or another standard reference. This medication will be administered

- [ ] Orally
- [ ] Injection
- [ ] Other – Specify:

### 1. Reason for Use of Psychotropic Medication and Benefits Expected (note if this is ‘Off-Label’ Use)
Include DSM-5 diagnosis or the diagnostic “working hypothesis.”

### 2. Alternative mode(s) of treatment other than OR in addition to medications include
Note: Some of these would be applicable only in an inpatient environment.

- [ ] Environment and/or staff changes
- [ ] Positive redirection and staff interaction
- [ ] Individual and/or group therapy
- [ ] Rehabilitation treatments/therapy (OT, PT, AT)
- [ ] Treatment programs and approaches (habilitation)
- [ ] Use of behavior intervention techniques

**Other Alternatives:**

### 3. Probable consequences of NOT receiving the proposed medication are

<table>
<thead>
<tr>
<th>Impairment of</th>
<th>Work Activities</th>
<th>Family Relationships</th>
<th>Social Functioning</th>
</tr>
</thead>
</table>

Possible increase in symptoms leading to potential

- [ ] Use of seclusion or restraint
- [ ] Limits on access to possessions
- [ ] Limits on personal freedoms
- [ ] Limit participation in treatment and activities
- [ ] Limits on recreation and leisure activities
- [ ] Intervention of law enforcement authorities
- [ ] Risk of harm to self or others

**Other Consequences:**

**Note:** These consequences may vary depending upon whether or not the individual is in an inpatient setting. It is also possible that in unusual situations, little or no adverse consequences may occur if the medications are not administered.

See Page 2

Client Initial __________ Date __________
4. Possible side effects, warnings, and cautions associated with this medication are listed below. This is not an all-inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text, such as the PDR. As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects in order to enhance care and treatment.

Continued – Possible side effects, warnings, and cautions associated with this medication.

**Most Common Side Effects**
The most common side effects include: Acid or sour stomach; anxiety; belching; constipation - difficulty having a bowel movement (stool); dry mouth; fear; headache; irregular heartbeats; irritability; lack or loss of strength; lightheadedness; nausea; need to keep moving; nervousness; rash; restlessness; shaking; sleepiness or unusual drowsiness; sleeplessness; stomach discomfort, upset, or pain; trouble sleeping; unable to sleep; vomiting; weight gain (children).

**Less Common Side Effects**
Less common side effects include: Bloating or swelling of face, arms, hands, lower legs, or feet; blurred vision; body aches or pain; congestion; coughing; difficulty in moving; fever; hoarseness; increased salivation- drooling (children); joint pain; muscle aching or cramping; muscle pains or stiffness; rapid weight gain; stuffy nose (children); swollen joints; tender, swollen glands in neck; tingling of hands or feet; tremor; trouble in swallowing; unusual weight gain or loss.

**Rare Side Effects**
Check with your healthcare professional immediately if any of the following side effects occur: Blurred vision; dizziness; headache; nervousness; slow or fast heartbeat; difficulty speaking; loss of balance control; muscle trembling, jerking, or stiffness; restlessness; shuffling walk; stiffness of limbs; twisting movements of body; uncontrolled movements, especially of face, neck, and back; worsening of behavior; thirsty, hungry, increased urination; or seizures.

**Caution**
Check with your healthcare professional immediately if any of the following rare side effects occur: Convulsions; difficulty in breathing; fast heartbeat; high fever; high or low blood pressure; increased sweating; lip smacking or puckering; loss of bladder control; muscle spasm or jerking of all extremities; puffing of cheeks; rapid or worm-like movements of tongue; severe muscle stiffness; sudden loss of consciousness; tiredness; uncontrolled chewing movements; uncontrolled movements of arms and legs; unusually pale skin.

**BLACK BOX WARNING**
*Increased Mortality in Elderly Patients with Dementia Related Psychosis:* Elderly patients with dementia related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of 17 placebo controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in the drug treated patients of between 1.6 to 1.7 times that seen in placebo treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug treated patients was about 4.5% compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.

*Suicidality and Antidepressant Drugs:* Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of adjunctive Abilify or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Abilify is not approved for use in pediatric patients with depression.

See PDR for an all-inclusive list of side effects.

---

**F-24277**

Medication: Abilify; Abilify Maintena: Aristada (aripiprazole)

**Client Initial**

**Date**
**Medication: Abilify; Abilify Maintena: Aristada (aripiprazole)**

By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:

1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather, it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.
2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.
3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client’s social worker, case manager, or psychologist.
4. I have the right to request a review at any time of my record, pursuant to § 51.30(4)(d) or § 51.30(5)(b).
5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client’s social worker, case manager, or agency/facility client rights specialist may be contacted for assistance.
6. My consent permits the dose to be changed within the anticipated dosage range without signing another consent.
7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s), and the probable consequences that may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate, and complete.
8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose.

<table>
<thead>
<tr>
<th>SIGNATURES</th>
<th>DATE SIGNED</th>
</tr>
</thead>
<tbody>
<tr>
<td>Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC)</td>
<td>Relationship to Client</td>
</tr>
<tr>
<td>Staff Present at Oral Discussion</td>
<td>Title</td>
</tr>
</tbody>
</table>

As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.

<table>
<thead>
<tr>
<th>Verbal Consent</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Obtained by – PRINT – Staff Name</td>
<td>Date Obtained</td>
</tr>
<tr>
<td>Obtained from – PRINT – Parent / Guardian (POA-HC) Name</td>
<td>Date Expires</td>
</tr>
</tbody>
</table>

Obtained from – PRINT – Parent / Guardian (POA-HC) Name

<table>
<thead>
<tr>
<th>Written Consent Received</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Obtained from – PRINT – Parent / Guardian (POA-HC) Name

<table>
<thead>
<tr>
<th>Date Received</th>
</tr>
</thead>
</table>

3

Client Initial __________  Date ______________